Answers are grounded in this paper and cite their sources.
p53 mutations are associated with increased metastatic potential of CaP. Abnormalities are found at approximately twice the frequency in metastases than in unselected samples of primary CaP, whereas in matched specimens there is a high rate of consonance. Mutant p53 may contribute to systemic therapy resistance, due to increased association with post-AA CaP specimens.
No takes yet. Share an insight, caveat, or question.
Meyers et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: